FDA Orders GLP-1 Labeling Changes Due to Eye Disease Risk


The Food and Drug Administration (FDA) introduced on November 9 that it’s going to require drugmakers so as to add info to the warning labels of Ozempic, Wegovy, Mounjaro, Zepbound and different GLP-1 drugs about “a possible elevated threat” of a uncommon eye situation known as nonarteritic anterior ischemic optic neuropathy (NAION).

GLP-1 drugs are accepted to deal with sort 2 diabetes and to assist folks drop pounds and hold it off.

NAION joins a growing list of side effects linked to GLP-1s, including a second eye warning to a number of labels.

The U.S. labels for Ozempic, Rybelsus, Trulicity, Mounjaro, and Zepbound already warn about diabetic retinopathy, a diabetes-related eye illness, in line with every drug’s prescribing info.

The 2 situations have an effect on totally different elements of the attention. Diabetic retinopathy damages tiny blood vessels within the retina, the layer in the back of the attention that senses gentle, in line with the National Eye Institute. NAION damages the optic nerve when it doesn’t get sufficient blood, in line with the FDA’s announcement.

Mihail Zilbermint, MD, director of endocrine hospitalists at Johns Hopkins, informed Healthline he hasn’t seen NAION in his sufferers. He has seen imaginative and prescient worsen in some folks after they begin a GLP-1.

“However we imagine that’s in all probability associated to speedy enchancment of their sugar management, which can be seen in somebody who’s beginning insulin,” Zilbermint stated.



Source link